– Based on a Review of Unblinded Data, an Independent Data Monitoring Committee (IDMC) Confirmed that Predetermined Futility Criteria Have Not Been Met –– IDMC Also Recommended Continuing Trial without Changes, Including no Need for a Potential Upsizing –– ENSURE Program Remains on Track to be Completed in 2026 –– Webcast to be Held Today, October 22, at 8:00 am ET –NEW YORK, Oct. 22, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administ ...